Among the agents studied, epcoritamab demonstrated the highest ORR...Cytokine release syndrome was the most common toxicity, predominantly grade 1-2, while neurotoxicity and hematologic adverse events were manageable. In conclusion, CD3×CD20 BsAbs exhibit meaningful efficacy and acceptable safety profiles in R/R LBCL patients following CAR-T failure, particularly in those with longer relapse intervals.

30 days ago

Retrospective data • Journal

CD20 (Membrane Spanning 4-Domains A1)

Epkinly (epcoritamab-bysp)

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma (clinicaltrials.gov)

P2, N=29, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting

1 month ago

Enrollment closed

lenalidomide • Epkinly (epcoritamab-bysp)

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)

P1/2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jun 2026 --> Feb 2026

1 month ago

Enrollment open • Trial initiation date

CD20 (Membrane Spanning 4-Domains A1)

CD20 positive

Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)

2ms

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)

P2, N=43, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Dec 2028 --> Oct 2029 | Initiation date: Dec 2026 --> Apr 2026 | Trial primary completion date: Dec 2028 --> Oct 2029

2 months ago

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date

CD20 (Membrane Spanning 4-Domains A1)

CD20 positive

gemcitabine • Rituxan (rituximab) • oxaliplatin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)

2ms

REBEL: External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL (clinicaltrials.gov)

P1, N=12, Not yet recruiting, University of Utah

2 months ago

New P1 trial

Epkinly (epcoritamab-bysp) • Columvi (glofitamab-gxbm)

2ms

HOVON 178 WM: Treatment of Waldenstroms macroglobulinemia with epcoritamab if the disease comes back during or after previous treatment (2025-522295-91-00)

P1/2, N=28, Not yet recruiting, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | N=14 --> 28

2 months ago

Enrollment change

CD20 positive

Epkinly (epcoritamab-bysp)

2ms

EPCORE DLBCL-4: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)

P3, N=379, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed

gemcitabine • Rituxan (rituximab) • lenalidomide • oxaliplatin • Epkinly (epcoritamab-bysp)

2ms

ECLAT: A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)

P2, N=0, Withdrawn, Memorial Sloan Kettering Cancer Center | N=27 --> 0 | Trial completion date: Aug 2028 --> Mar 2026 | Recruiting --> Withdrawn | Trial primary completion date: Aug 2028 --> Mar 2026

2 months ago

Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date

CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD4 (CD4 Molecule)

lenalidomide • Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)